{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:24:04Z","timestamp":1784334244757,"version":"3.55.0"},"reference-count":50,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2003,6,10]],"date-time":"2003-06-10T00:00:00Z","timestamp":1055203200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Gastro and Hepatol"],"published-print":{"date-parts":[[2003,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background:<\/jats:bold> Resistance to metronidazole is one of the most common reasons for <jats:italic>Helicobacter pylori<\/jats:italic> treatment failure with classic triple therapy. In contrast, the clarithromycin\u2010based regimen is not cost\u2010effective for developing countries. Furazolidone is a very good substitute for metronidazole and clarithromycin, but its many side\u2010effects limit widespread use. The aim of the present study was to assess the efficacy of two different doses of furazolidone in combination with amoxycillin and omeprazole.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> A total of 123 patients with duodenal ulcer were randomized and received the following medications for two weeks. Group A: furazolidone 2\u2003\u00d7\u2003200\u2003mg\u2003+\u2003amoxycillin 2\u2003\u00d7\u20031\u2003g\u2003+\u2003omeprazole 2\u2003\u00d7\u200320\u2003mg\/day. Group B: furazolidone 2\u2003\u00d7\u200350\u2003mg\u2003+\u2003amoxycillin 2\u2003\u00d7\u20031\u2003g\u2003+\u2003omeprazole 2\u2003\u00d7\u200320\u2003mg\/day. Control endoscopy was performed after 6\u2003weeks and two biopsy specimens from the antrum and two from the corpus were taken for a urease test and histology. Eradication was concluded if all tests were negative for <jats:italic>H.\u2003pylori<\/jats:italic>.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> In total, 110 patients completed the study. Four patients in group A did not tolerate the regimen on day\u20038 of therapy and were excluded from the study. Serious complications such as fever, and fatigue and dizziness, which occurred in the beginning of the second week of treatment (days 8\u201310), were more common in group A than in group B (19%, 15.9% and 14.3%, respectively, in group A <jats:italic>vs<\/jats:italic> 0% in group B). The eradication rate by per protocol analysis was significantly higher in group A than in group B (88.9%<jats:italic>vs<\/jats:italic> 67.9%, respectively, <jats:italic>P<\/jats:italic>\u2003=\u20030.008). However, this difference was low and not statistically significant by intention\u2010to\u2010treat analysis (76.2% in group A and 62.3% in group B, <jats:italic>P<\/jats:italic>\u2003=\u20030.09).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> The regimen with a non\u2010reduced dose of furazolidone in combination with amoxycillin and omeprazole was effective when the patients tolerated the drugs and completed the study.<\/jats:p><jats:p>\u00a9 2003 Blackwell Publishing Asia Pty Ltd<\/jats:p>","DOI":"10.1046\/j.1440-1746.2003.03058.x","type":"journal-article","created":{"date-parts":[[2003,6,10]],"date-time":"2003-06-10T07:14:06Z","timestamp":1055229246000},"page":"778-782","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Effect of different doses of furazolidone with amoxicillin and omeprazole on eradication of <i>Helicobacter pylori<\/i>"],"prefix":"10.1111","volume":"18","author":[{"given":"HASSAN SALMAN","family":"ROGHANI","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SEDEGH","family":"MASSARRAT","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MOHAMMAD","family":"SHIREKHODA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZIA","family":"BUTORAB","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2003,6,10]]},"reference":[{"key":"e_1_2_5_2_2","first-page":"S59","article-title":"The prevalence of Helicobacter pylori in peptic ulcer disease (Review)","volume":"9","author":"Kuipers EJ","year":"1995","journal-title":"Aliment. Pharmacol. Ther."},{"key":"e_1_2_5_3_2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.1994.03520010077036","article-title":"Helicobacter pylori in peptic disease. NIH consensus conference","volume":"272","author":"NIH consensus development panel on Helicobacter pylori ulcer disease.","year":"1994","journal-title":"JAMA"},{"key":"e_1_2_5_4_2","first-page":"2025","article-title":"Helicobacter pylori recurrence after successful eradication: 5 year follow up in the United States","volume":"92","author":"Abu\u2010Mahfouz MZ","year":"1997","journal-title":"Am. J. Gastroenterol."},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1994.tb00303.x"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.320.7226.31"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(97)80025-X"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.2174\/1381612003399077"},{"key":"e_1_2_5_9_2","first-page":"314","article-title":"Usefulness of new triple therapy containing PPI","volume":"59","author":"Tanabe H","year":"2001","journal-title":"Nippon Rinsho"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.00931.x"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-5378.1996.tb00003.x"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1998.00212.x"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200108000-00007"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-199810000-00006"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-199907000-00004"},{"key":"e_1_2_5_16_2","first-page":"419","article-title":"Effect of triple therapy or amoxycillin plus omperazole or amoxycillin plus tinidazole plus omperazole on duodenal ulcer healing, eradication of Helicobacter Pylori and prevention of ulcer relapse over a 1 year follow\u2010up period: a prospective randomized controlled study","volume":"90","author":"Saber\u2010Firoozi M","year":"1995","journal-title":"Am. J. Gastroentrol."},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(86)92639-5"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1997.00172.x"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.1.306-308.2001"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00709.x"},{"key":"e_1_2_5_21_2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1155\/1999\/485237","article-title":"Helicobacter pylori: novel therapies","volume":"13","author":"Drouin E","year":"1999","journal-title":"Can. J. Gastroenterol."},{"key":"e_1_2_5_22_2","first-page":"116","article-title":"Helicobacter pylori","volume":"89","author":"Marshall BJ","year":"1994","journal-title":"Am. J. Gastroenterol."},{"key":"e_1_2_5_23_2","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/978-94-009-1792-7_31","volume-title":"Aspects of Anti\u2010Helicobacter pylori, Basic Mechanism to Clinical Cure 1996","author":"Tytgat GNJ.","year":"1996"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/47.4.459"},{"key":"e_1_2_5_25_2","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1046\/j.1365-2036.1999.00653.x","article-title":"Omeprazole, Clarithromycin and Furazolidone for the eradication of Helicobacter pylori in patient with duodenal ulcer","volume":"13","author":"Dani R","year":"2000","journal-title":"Aliment. Pharmacol. Ther."},{"key":"e_1_2_5_26_2","first-page":"A14","article-title":"Effectiveness of Helicobacter pylori treatment regimens in clinical practice: a community based outcomes study","volume":"112","author":"Fennerty M","year":"1997","journal-title":"Gastroentrology"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.11.s1.11.x"},{"key":"e_1_2_5_28_2","first-page":"A105","article-title":"Metronidazol and claritromycin resistance among Helicobacter pylori isolates from a large hospital in the United States (Abstract)","volume":"112","author":"Osato MS","year":"1997","journal-title":"Gastroenterology"},{"key":"e_1_2_5_29_2","first-page":"A236","article-title":"Metronidazole resistance is high in Korea and Colombia and appears to be rapidly increasing in the US (Abstract)","volume":"110","author":"Reddy R","year":"1996","journal-title":"Gastroenterology"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-5378.2000.0050S1023.x"},{"key":"e_1_2_5_31_2","first-page":"214","article-title":"European Consensus Guidelines identify acid pump inhibitor based triple therapy as today's treatment of choice for Helicobacter pylori eradication","volume":"89","author":"No authors listed.","year":"1996","journal-title":"Ir. Med. J."},{"key":"e_1_2_5_32_2","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1155\/2000\/604563","article-title":"Consensus guidelines: agreement and debate surrounding the optimal management of Helicobacter pylori infection","volume":"14","author":"McNamara D","year":"2000","journal-title":"Can. J. Gastroenterol."},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(98)80860-3"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1994.tb00170.x"},{"key":"e_1_2_5_35_2","first-page":"1203","article-title":"Clarithromycin, tetracycline, and bismuth: a new non\u2010metronidazole therapy for Helicobacter pylori infection","volume":"89","author":"Al\u2010Assi AT","year":"1994","journal-title":"Am. J. Gastroenterol."},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)92962-2"},{"key":"e_1_2_5_37_2","first-page":"738","volume-title":"Basic and Clinical Pharmacology","author":"Jawetz E","year":"1995"},{"key":"e_1_2_5_38_2","unstructured":"SmithJN.Drugs used to treat amebiasis and other intestinal protozoal infections. In:ClarkWG BraterDC JohnsonAR eds.Goth's Medical Pharmacology 13th edn. St. Louis:Mosby 1992;689."},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365528909091325"},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1997.00166.x"},{"key":"e_1_2_5_41_2","first-page":"503","article-title":"The efficacy of Furazolidone and Metronidazole in the treatment of chronic gastritis associated with Helicobacter pylori. A randomized double blind controlled trial","volume":"37","author":"Xiao SD","year":"1990","journal-title":"Hepatogastroenterology"},{"key":"e_1_2_5_42_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00845.x"},{"key":"e_1_2_5_43_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00492.x"},{"key":"e_1_2_5_44_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.00895.x"},{"key":"e_1_2_5_45_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-5378.2000.00011.x"},{"key":"e_1_2_5_46_2","first-page":"A244","article-title":"Antibiotic resistance of Helicobacter pylori to antibiotics in Iran","volume":"116","author":"Malekzadeh R","year":"1999","journal-title":"Gastroenterology"},{"key":"e_1_2_5_47_2","volume-title":"Goodman and Gillman's Pharmacological basis of therapeutics","author":"Gilman AG","year":"1991"},{"key":"e_1_2_5_48_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365528909091336"},{"key":"e_1_2_5_49_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.9.1637"},{"key":"e_1_2_5_50_2","first-page":"803","article-title":"[Clarithromycin combined short\u2010term triple therapies for eradication of Helicobacter pylori infection.]","volume":"35","author":"Liu W","year":"1996","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"e_1_2_5_51_2","first-page":"162","article-title":"Five day and ten day triple therapy (amoxicillin, furazolidone and metronidazole) in the treatment of duodenal ulcer","volume":"51","author":"Zeterka S","year":"1996","journal-title":"Rev. Hosp. Clin. Fac. Med. Sao Paulo"}],"container-title":["Journal of Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1440-1746.2003.03058.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1440-1746.2003.03058.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T05:48:09Z","timestamp":1697176089000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1440-1746.2003.03058.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,6,10]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2003,7]]}},"alternative-id":["10.1046\/j.1440-1746.2003.03058.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1440-1746.2003.03058.x","archive":["Portico"],"relation":{},"ISSN":["0815-9319","1440-1746"],"issn-type":[{"value":"0815-9319","type":"print"},{"value":"1440-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,6,10]]},"assertion":[{"value":"2003-06-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}